Τίτλος:
Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term. © 2021
Συγγραφείς:
Hirschberg, A.L.
Bitzer, J.
Cano, A.
Ceausu, I.
Chedraui, P.
Durmusoglu, F.
Erkkola, R.
Goulis, D.G.
Kiesel, L.
Lopes, P.
Pines, A.
van Trotsenburg, M.
Lambrinoudaki, I.
Rees, M.
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
emollient agent; estrogen; lubricating agent; estrogen, application site irritation; Article; breast cancer; breast tenderness; cancer adjuvant therapy; cancer risk; candidiasis; cardiovascular disease; cardiovascular risk; consensus; drug efficacy; drug safety; drug use; endometrium cancer; female; female genital tract cancer; hip fracture; human; information retrieval; low drug dose; Medline; meta analysis (topic); ovary cancer; peritoneum cancer; postmenopause; publication; randomized controlled trial (topic); recurrent disease; systematic review (topic); topical treatment; urinary tract infection; urine incontinence; uterine cervix cancer; uterine tube tumor; uterus sarcoma; vagina atrophy; vagina bleeding; vagina cancer; vagina discharge (disease); vagina mycosis; vaginitis; venous thromboembolism; atrophy; expert witness; intravaginal drug administration; practice guideline; quality of life; vagina disease; vulva disease, Administration, Intravaginal; Atrophy; Estrogens; Expert Testimony; Female; Humans; Postmenopause; Practice Guidelines as Topic; Quality of Life; Vaginal Diseases; Vulvar Diseases
DOI:
10.1016/j.maturitas.2021.04.005
